Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long time immunogenicity of measles vaccine in the vaccination era: An open question.

Literature DB >> 27668886

Long time immunogenicity of measles vaccine in the vaccination era: An open question.

Maria Serena Gallone¹, Cinzia Germinario¹, Angela Larocca², Silvio Tafuri¹.

Abstract

After WHO European Region determined the 2005 - 2010 Strategic Plan for measles elimination, the number of reported measles cases in Europe fell dramatically. This decrease is related to the vaccination strategy carried out by European countries. This extensive immunization strategy changes the epidemiological patter and could influence the effectiveness and the long-time immunogenicity of the vaccine. To evaluate the long-time immunogenicity of the measles vaccine in the vaccination era, a pilot study among vaccinated blood donors in Apulia was designed. Of 174 enrolled patients, 93.7% presented an anti-measles IgG titer positive. GMT seems to increase by age (p = 0.001). The GMT seems to increase by age and this could be related to the exposition to natural boosters, that was more probable before the beginning of universal mass vaccination against measles. Future studies have to focus the correlation between GMT and age.

Entities: Chemical Species

Keywords: anti-measles IgG; geometric mean titer; measles elimination; vaccination strategy

Mesh：

Substances：

Year: 2016 PMID： 27668886 PMCID： PMC5287334 DOI： 10.1080/21645515.2016.1227519

Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 3.452

11 in total

1. An outbreak of measles in Apulia, Italy, November 2006-January 2007.

Authors: R Prato; M Chironna; G Caputi; A Sallustio; D Martinelli; A Falco; C A Germinario
Journal: Euro Surveill Date: 2007-04-05

2. An outbreak of measles including nosocomial transmission in Apulia, south-east Italy, January-March 2008--a preliminary report.

Authors: G Caputi; S Tafuri; M Chironna; D Martinelli; A Sallustio; A Falco; C A Germinario; R Prato; M Quarto
Journal: Euro Surveill Date: 2008-04-17

3. What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003-2009 and essential accelerated actions.

Authors: Rebecca Martin; Steven Wassilak; Nedret Emiroglu; Amra Uzicanin; Sergei Deshesvoi; Dragan Jankovic; Ajay Goel; Nino Khetsuriani
Journal: J Infect Dis Date: 2011-07 Impact factor: 5.226

4. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Authors: Markus Knuf; Fred Zepp; Klaus Helm; Hartwig Maurer; Albrecht Prieler; Dorothee Kieninger-Baum; Martine Douha; Paul Willems
Journal: Eur J Pediatr Date: 2011-09-21 Impact factor: 3.183

Review 5. Pertussis vaccines and the challenge of inducing durable immunity.

Authors: Jason M Warfel; Kathryn M Edwards
Journal: Curr Opin Immunol Date: 2015-06-17 Impact factor: 7.486

6. Letter to the editor: measles on the cruise ship: links with virus spreading into an emergency department in Southern Italy.

Authors: V Cozza; M Chironna; C Leo; R Prato
Journal: Euro Surveill Date: 2014-05-15

7. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.

Authors: Maria Paulke-Korinek; Gustav Fischmeister; Ana Grac; Pamela Rendi-Wagner; Michael Kundi; Afsaneh Mohsenzadeh-Rabbani; Katharina Moritz; Beate Fenninger; Reinhart Jarisch; Joanna Jasinska; Heidemarie Holzmann; Ursula Wiedermann; Herwig Kollaritsch
Journal: Vaccine Date: 2011-05-30 Impact factor: 3.641

8. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.

Authors: Chin-Yun Lee; Ren-Bin Tang; Fu-Yuan Huang; Haiwen Tang; Li-Min Huang; Hans L Bock
Journal: Int J Infect Dis Date: 2002-09 Impact factor: 3.623

Long time immunogenicity of measles vaccine in the vaccination era: An open question.

1. An outbreak of measles in Apulia, Italy, November 2006-January 2007.

2. An outbreak of measles including nosocomial transmission in Apulia, south-east Italy, January-March 2008--a preliminary report.

3. What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003-2009 and essential accelerated actions.

4. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Review 5. Pertussis vaccines and the challenge of inducing durable immunity.

6. Letter to the editor: measles on the cruise ship: links with virus spreading into an emergency department in Southern Italy.

7. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.

8. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.

9. [The State of Measles and Rubella in the WHO European region].

10. Genetic characterization of measles virus strains isolated during an epidemic cluster in Puglia, Italy 2006-2007.

1. Seroprevalence for vaccine-preventable diseases among Italian healthcare workers.

2. Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study.

3. Seroprevalence of IgG antibodies against measles in a selected Polish population - do we need to be re-vaccinated?

4. Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study.